On April 18, 2022 Aadi Bioscience, Inc. ("Aadi") (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate at the Jefferies "Biotech on the Bay" Summit, to be held in-person in Miami, FL April 26-27, 2022 (Press release, Aadi Bioscience, APR 18, 2022, View Source [SID1234614202]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Aadi executive team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Jefferies to register for a meeting with the company.